Trial 3G-21-1


Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Syma Iqbal, M.D.
Other Trial Staff:  Victoria Amran, Coordinator, Charlean Ketchens, R.N., Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Mary Ordaz, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Niranjan Bhatt, D.M., Rabia Rehman, Coordinator, Raian Fahim, D.M., Angela Smith Bryant, Coordinator, Eva Ritzmann, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.